Welcome to ALTG
ALTG awarded $12 million in funding
The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.
New ALTG Study ILLUMINATE
ALTG Study, ILLUMINATE Study (ALTG 16/009) is now open to recruitment. This is a phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor (EGFR) mutation Tyrosine Kinase Inhibitors (TKIs).
- Helpful links
Many links to all kinds of useful and reputable information.
A list of support information and consumer organisations
- Clinical Trials
Upcoming EventsUpcoming Events
February 19 - February 21
February 19 @ 2:00 pm - 5:00 pm
February 20 @ 7:00 am - 8:00 am
February 21 @ 7:00 am - 9:00 am
October 23 @ 8:00 am - October 24 @ 5:00 pm